Free Research Reports on These Drug Delivery Stocks -- Alkermes, PetMed Express, Valeant Pharma, and Adamis Pharma

Tuesday, April 3, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 3, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community.

Today we are offering reports on ALKS, PETS, VRX, and ADMP which can be accessed for free by signing up to Featured today on are the following stocks: Alkermes PLC (NASDAQ: ALKS), PetMed Express
Inc. (NASDAQ: PETS), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Adamis Pharmaceuticals Corp.  (NASDAQ: ADMP). These companies are part of the Drug Delivery space, which markets and ships prescription and non-prescription medications for human and animal use, along with other health products. All you have to do is sign up today for this free limited time offer by clicking the link below.


Dublin, Ireland headquartered Alkermes PLC's stock finished Monday's session 21.96% lower at $45.23. A total volume of 8.05 million shares was traded, which was above their three months average volume of 994,240 shares. Shares of the Company are trading below their 200-day moving average by 17.06%. Moreover, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the US, Ireland, and internationally, have a Relative Strength Index (RSI) of 26.28.  

On April 02nd, 2018, research firm Evercore ISI downgraded the Company's stock rating from 'Outperform' to 'In-line'.

On April 02nd, 2018, Alkermes announced that it received a Refusal to File letter from the US FDA regarding its New Drug Application for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies. The Company strongly disagrees with the FDA's conclusions and plans to appeal the decision. Get the full research report on ALKS for free by clicking below at:

PetMed Express

Shares in Delray Beach, Florida headquartered PetMed Express Inc. declined 1.27%, ending yesterday's session at $41.22 with a total trading volume of 486,519 shares. The stock has surged 105.69% over the past year. The Company's shares are trading 1.59% below their 200-day moving average. Moreover, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 37.81. Find your free research report on PETS at:

Valeant Pharmaceuticals International

On Monday, Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock dropped 5.34%, to close the day at $15.07. A total volume of 7.74 million shares was traded. The Company's shares have advanced 36.01% over the past year. The stock is trading 8.15% below its 200-day moving average. Additionally, shares of Valeant Pharma, which operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter products, and medical devices, have an RSI of 38.89. 

On March 26th, 2018, Valeant Pharma announced that all terms and conditions of the pending cash tender offers by the Company and its subsidiary, Valeant Pharmaceuticals, to purchase up to $1,500,000,000 aggregate principal amount of their respective outstanding notes remain unchanged, as set forth in the Offer to Purchase dated March 12th, 2018. The tender offers remain open and will expire at 11:59 p.m. New York City Time on April 09th, 2018.  Sign up today for the free research report on VRX at:

Adamis Pharmaceuticals

Shares in San Diego, California headquartered Adamis Pharmaceuticals Corp.  ended the day 2.86% lower at $3.40. A total volume of 340,554 shares was traded. The stock is trading below its 50-day moving average by 5.05%. Furthermore, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 46.33.

On March 23rd, 2018, research firm B. Riley FBR, Inc. reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $6.25 a share to $7.50 a share. Wall St. Equities' research coverage also includes the downloadable free report on ADMP at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store